AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 222.49B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 6.99B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.48 |
| PE Ratio | 32.04 |
| Forward PE | 19.14 |
| Dividend | 2.45 (1.71%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 250,205 |
| Average Volume | 2,084,280 |
| Open | 14,326 |
| Previous Close | 14,346 |
| Day's Range | 14,266 - 14,410 |
| 52-Week Range | 9,574 - 15,474 |
| Beta | 0.19 |
| RSI | 63.24 |
| Earnings Date | Feb 10, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
Astrazeneca (AZN) closed the most recent trading day at $96.34, moving +1.94% from the previous trading session.
Miners Boost FTSE 100 as Gold Hits Record
FTSE 100 lifted by miners and gold, Pearson and Mirriad fell; AstraZeneca and Truetide advanced. The post Miners Boost FTSE 100 as Gold Hits Record appeared first on Investomania .
AstraZeneca (AZN) Gains Approval in China for Key Lung Cancer Treatment
AstraZeneca (AZN) Gains Approval in China for Key Lung Cancer Treatment
AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AstraZeneca (AZN) Awaits Conclusion of US Pharma Import Probe
AstraZeneca (AZN) Awaits Conclusion of US Pharma Import Probe
AstraZeneca (AZN) Broadens Oncology Efforts with Acquisition of ModellaAI
AstraZeneca (AZN) Broadens Oncology Efforts with Acquisition of ModellaAI
Walmart Stock Hits All-Time High Amid Nasdaq-100 Inclusion
Walmart Inc (NASDAQ: WMT) shares are up on Tuesday following the announcement that the company will join the Nasdaq-100 index. Here’s what investors need to know after the stock hits a new all-time. ...
AstraZeneca to acquire Modella AI to speed oncology drug research
AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale
BOSTON--(BUSINESS WIRE)-- #AstraZeneca--Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale.
AstraZeneca (AZN) Joins in Groundbreaking Genetic Research Initiative
AstraZeneca (AZN) Joins in Groundbreaking Genetic Research Initiative
AstraZeneca (AZN) Progresses with Phase 3 TROPION-Lung17 Trial
AstraZeneca (AZN) Progresses with Phase 3 TROPION-Lung17 Trial
AstraZeneca (AZN) Set for Removal from Several Key Nasdaq Indexes
AstraZeneca (AZN) Set for Removal from Several Key Nasdaq Indexes
Nasdaq-100 reshuffle: Walmart set to join US stock market index; to replace AstraZeneca from January 20
International Business News: Popular retail corporation Walmart is soon going to become a part of the Nasdaq-100 Index in the US, from January 20. It will replace British pharmace.
AstraZeneca: Oncology Dominance Justifies New All-Time Highs
Walmart to replace AstraZeneca on Nasdaq 100 effective Jan. 20
Walmart (WMT) Joins Nasdaq-100 Index, Replacing AstraZeneca (AZN)
Walmart (WMT) Joins Nasdaq-100 Index, Replacing AstraZeneca (AZN)
Walmart To Join Nasdaq-100 Index As AstraZeneca Exits In January 2026 Reshuffle
(RTTNews) - Nasdaq (NDAQ) announced that Walmart Inc. (WMT) will join the Nasdaq-100 Index (NDX), the Nasdaq-100 Equal Weighted Index (NDXE), and the Nasdaq-100 Ex-Tech Sector Index (NDXX). The inclus...
Walmart to Join Nasdaq-100, Replacing AstraZeneca
Walmart to Join Nasdaq-100, Replacing AstraZeneca
Healthy Returns: What to expect from pharma at the JPM conference
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Astrazeneca (AZN) concluded the recent trading session at $94.01, signifying a -1.21% move from its prior day's close.
AstraZeneca names Rick Suarez head of US biopharmaceuticals unit
AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the drugmaker's previously announced $50 billion research, development and manufac...
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the C...
BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, scienc...
AstraZeneca's (AZN) Saphnelo Shows Promising Phase III Results
AstraZeneca's (AZN) Saphnelo Shows Promising Phase III Results
AstraZeneca's Self-Injectable Lupus Drug Shines In Late-Stage Trial
On Tuesday, AstraZeneca Plc (NASDAQ: AZN) released complete results from the Phase 3 TULIP-SC trial of a subcutaneous (SC) administration of anifrolumab versus placebo in participants aged 18 to 70 y...